Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is attractive because its NeXT Personal MRD test has achieved strong clinical traction, with Q1'26 molecular clinical test volume of 7,815, up 258% Y/Y and 26% q/q, while over 1,000 oncologists were ordering the assay and Medicare coverage wins improved reimbursement visibility. The company also has a growing biopharma MRD business tracking to about $20M in 2026 and valuable sequencing and tumor-profiling capabilities that support personalized cancer vaccines, adding diversified revenue streams beyond clinical diagnostics. Although gross margin compressed from 32% in 2024 to 23% in 2025 and 2% in Q1'26 as commercialization costs were absorbed, the strategic combination with Tempus should provide greater scale, a larger sales force, and a path to accelerate growth in a very large MRD market.

Bears say

Personalis is viewed negatively because its economics remain weak, with Q1’26 gross margin at just 2% and operating losses continuing despite $15.5M of revenue and $233M of cash, underscoring heavy burn and limited near-term profitability. The company’s growth story is also fragile because biopharma ordering can be volatile quarter-to-quarter, large pharma demand for personalized cancer vaccines may soften, and reimbursement for its MRD test may come in below expectations. Even with the announced TEM acquisition, the stock trades very close to deal value, leaving little upside while execution risks, partner dependence, and the possibility that the deal does not close keep the risk/reward unattractive.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.